Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers
Juliet D. French(The University of Queensland), Isabel dos‐Santos‐Silva(London School of Hygiene & Tropical Medicine), Marjanka K. Schmidt(University of Cambridge), Jonathan P. Tyrer(University of Cambridge), Joshua A. Betts(The University of Queensland), Julian Peto(London School of Hygiene & Tropical Medicine), Andrew Beck(Beth Israel Deaconess Medical Center), Peter A. Fasching(Universitätsklinikum Erlangen), Daniel C. Tessier(McGill University and Génome Québec Innovation Centre), Shahana Ahmed(University of Cambridge), Annegien Broeks, Pornthep Siriwanarangsan(Ministry of Public Health), Joe Dennis(University of Cambridge), Kenneth Muir(Manchester Academic Health Science Centre), Caroline Baynes(University of Cambridge), Sarah Stewart‐Brown(University of Warwick), Ana-Teresa Maia(Cancer Research UK), Anna González‐Neira(Spanish National Cancer Research Centre), Sten Cornelissen, Arif B. Ekici(University Medical Center Groningen), Kyriaki Michailidou(Cyprus Institute of Neurology and Genetics), Craig Luccarini(University of Cambridge), Ed Dicks(Institute of Cancer Research), Sofia Khan(University of Helsinki), Nicholas Knoblauch(Beth Israel Deaconess Medical Center), Daniel R. Barnes(University of Cambridge), Peter Kraft(National Cancer Institute), Constance Chen(Harvard University), Maya Ghoussaini(Regeneron (United States)), Stacey L. Edwards(Queensland University of Technology), Christian R. Loehberg, Don Conroy(University of Cambridge), Mel Maranian(University of Cambridge), Melissa C. Southey(The University of Melbourne), Qin Wang(University of Cambridge), Daniel Vincent(The Netherlands Cancer Institute), Thomas Carroll(University of Dundee), Peter J. Bailey(Cambridge University Hospitals NHS Foundation Trust), Kerstin B. Meyer(Siriraj Hospital), Matthias W. Beckmann, John L. Hopper(The University of Melbourne), Artitaya Lophatananon(University of Warwick), M. Rosario Alonso(Spanish National Cancer Research Centre), Senno Verhoef(The Netherlands Cancer Institute), Daniel Herrero(Spanish National Cancer Research Centre), Manjeet K. Bolla(University of Cambridge), François Bacot(The Netherlands Cancer Institute), Kristine M. Hillman(The University of Queensland), Jonathan Beesley(QIMR Berghofer Medical Research Institute), Martin O’Reilly(Cancer Research UK)
Cited by 214
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Patterns of somatic mutation in human cancer genomes
|Nature|2007|3.1k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k